Evidence map›Paper›PMID 41779337›Full record

ArticleAnnals of nuclear medicine2026

Assessment of environmental radioactive contamination in radiation therapy rooms: comparison between therapy after Lu-177 DOTATATE and I-131.

Reiko Ideguchi, Aliya Toilybayeva, Ryo Toya, Sumi Yokoyama, Takashi Kudo

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Reiko IdeguchiDepartment of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Sakamoto 1-12-4, Nagasaki, 852-8523, Japan. rideguchi@nagasaki-u.ac.jp.ORCID http://orcid.org/0000-0003-4283-2473
Aliya ToilybayevaDepartment of Radioisotope Medicine, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto 1-12-4, Nagasaki, 852-8523, Japan.
Ryo ToyaDepartment of Radiology, Nagasaki University Hospital, Sakamoto 1-7-1, Nagasaki, 852-8501, Japan.
Sumi YokoyamaDepartment of Radiation Biology and Protection, Atomic Bomb Disease Institute, Nagasaki University, Sakamoto 1-12-4, Nagasaki, 852-8523, Japan.
Takashi KudoDepartment of Radioisotope Medicine, Atomic Bomb Disease Institute, Nagasaki University, Sakamoto 1-12-4, Nagasaki, 852-8523, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study investigated the actual state of remnant radioactive contamination in hospital rooms after Lu-177 DOTATATE radioisotope therapy for neuroendocrine tumors and compared it with that after I-131 radioisotope therapy for thyroid cancer. Furthermore, we aimed to obtain basic data to consider the appropriateness of the restrictions in Japan.

methodsIn this study, 20 rooms for Lu-177 DOTATATE radioisotope therapy and 31 rooms for I-131 radioisotope therapy treated between April 2024 and April 2025 were evaluated. The ambient radiation level was monitored; surface contamination was measured using a GM surface contamination monitor; and removable surface contamination was quantified.

resultsThe remnant contamination of the radioisotope therapy room after treatment with Lu-177 DOTATATE was significantly lower than that after treatment with I-131 after patient discharge. For Lu-177 DOTATATE, a high ambient dose was observed only at the bedside and shower room, and high surface contamination was only found in the toilet bowl.

conclusionsThe remnant ambient dose/contamination in the room after Lu-177 DOTATATE therapy was limited compared with that after I-131 therapy. We believe that the findings of this study will guide the development of more proper and suitable strategies for managing Lu-177 DOTATATE therapy.

Indexed as

Iodine RadioisotopesOctreotideOrganometallic CompoundsHumansNeuroendocrine TumorsThyroid NeoplasmsIodine-131Iodine Radioisotopeslutetium Lu 177 dotatateOctreotideOrganometallic CompoundsI-131Lu-177 DOTATATERemnant radioactive contamination

Identifiers

PMID41779337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.